1. 2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age. (26th November 2018) Authors: Otten, Gillis; Matassa, Vince; Ciarlet, Max; Leav, Brett Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2556. Retrospective Evaluation of Mismatch From Egg-Based Isolation of Influenza Strains Compared With Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness. (26th November 2018) Authors: Rajaram, S; Van Boxmeer, Josephine; Leav, Brett; Suphaphiphat, Pirada; Iheanacho, Ike; Kistler, Kristin Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study. (26th November 2018) Authors: Daly, Wendy; Ramsey, Keith; Forsten, Aino; Heijnen, Esther; Leav, Brett; Oberye, Janine; Zhang, Bin; Pacciarini, Filippo; Vesikari, Timo Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Issue 35 (19th August 2022) Authors: Leav, Brett; Straus, Walter; White, Phil; Leav, Alison; Gaines, Tashawnee; Maggiacomo, Grace; Kim, Denny; Smith, Emily R.; Gurwith, Marc; Chen, Robert T. Journal: Vaccine Issue: Volume 40:Issue 35(2022) Page Start: 5275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age. Issue 3 (16th January 2020) Authors: Otten, Gillis; Matassa, Vincent; Ciarlet, Max; Leav, Brett Journal: Vaccine Issue: Volume 38:Issue 3(2020) Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Issue 20 (12th May 2021) Authors: Chu, Laurence; McPhee, Roderick; Huang, Wenmei; Bennett, Hamilton; Pajon, Rolando; Nestorova, Biliana; Leav, Brett Journal: Vaccine Issue: Volume 39:Issue 20(2021) Page Start: 2791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. (August 2019) Authors: Lindert, Kelly; Leav, Brett; Heijnen, Esther; Barrett, Julia; Nicolay, Uwe Journal: International journal of infectious diseases Issue: Volume 85(2019)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Issue 5 (May 2018) Authors: Vesikari, Timo; Kirstein, Judith; Devota Go, Grace; Leav, Brett; Ruzycky, Mary Ellen; Isakov, Leah; de Bruijn, Marianne; Oberye, Janine; Heijnen, Esther Journal: Lancet Issue: Volume 6:Issue 5(2018) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. (10th May 2022) Authors: El Sahly, Hana M; Baden, Lindsey R; Essink, Brandon; Montefiori, David; McDermont, Adrian; Rupp, Richard; Lewis, Michael; Swaminathan, Shobha; Griffin, Carl; Fragoso, Veronica; Miller, Vicki E; Girard, Bethany; Paila, Yamuna D; Deng, Weiping; Tomassini, Joanne E; Paris, Robert; Schödel, Florian; ... Journal: Journal of infectious diseases Issue: Volume 226:Number 10(2022) Page Start: 1731 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. (August 2019) Authors: Nicolay, Uwe; Heijnen, Esther; Nacci, Pantaleo; Patriarca, Peter A.; Leav, Brett Journal: International journal of infectious diseases Issue: Volume 85(2019)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗